MCRA Helps Small Spine Companies
This article was originally published in Start Up
Executive Summary
Clinical trials strategies, particularly in the medical device industry, can confer an important competitive advantage to a company-or present a stumbling block that costs time, money, and markets. This is particularly true in orthopedics, where development lead times stretch into years. In hip, knee, and spine surgery, companies with new technologies can enjoy first-mover advantages that let them dominate markets for five, even ten years, but market delays can undercut such advantages. That's why Viscogliosi Brothers LLC, a venture capital firm/merchant bank focused exclusively on the musculoskeletal industries, recently formed Musculoskeletal Clinical Regulatory Advisors LLC (MCRA), a firm that aims to help orthopedics start-ups develop and execute clinical research strategies.
You may also be interested in...
Spine-Bending Market
Today, the market for spine surgery is growing by more than 20% annually based on fusion technologies alone, despite the fact that those technologies are decades old and flawed. However, a heightened awareness of the clinical drawbacks of fusion is fueling prolific company creation in a new spine motion preservation segment of the industry. Some 118 start-ups in spine are dotting the landscape. Many hope to offer new devices that address spinal joint reconstruction; artificial discs, disc nuclei, annulus repair, facet joint replacement, and dynamic or flexible stabilization of the spine.
‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs
As it stands, drugmakers will have just 90 days to prepare their dossiers for EU-wide joint clinical assessments under the new Health Technology Assessment Regulation. Market access experts from EFPIA tell the Pink Sheet that this short deadline could delay patient access to complex medicines, such as innovative cancer drugs.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.